C4 Therapeutics Inc (CCCC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.95-5.45%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CCCC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -6.7% |
| Our one-year growth estimate | diamond | -27.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 20.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
CCCC — litigation filed
Dated 2026-09-25
Other Events. On September 25, 2026, the Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma ( “ RRMM ”) , as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide in combination with elranatamab (ELREXFIO ® ), which are being presented in a poster presentation at the 23rd International Myeloma Society (IMS) Annual Meetin…
Why it matters: This trial tests cemsidomide with two approved myeloma drug combinations. Starting on time adds another test of its use in combination treatment.
Supportive ifC4T reports that the Phase 1b trial has started by June 30, 2027, with both planned treatment arms.
Worry ifThe trial has not started by June 30, 2027, or C4T removes either planned treatment arm.
Why it matters: C4T is loss-making and uses cash to run its trials. Its latest update says cash can fund operations through the end of 2028.
Worry ifA later company update says its cash will last until at least December 31, 2028. It does not need new financing to do so.
Less concerning ifC4T says its cash will last only until before December 31, 2028, or that it needs new financing for planned trials.
Why it matters: MOMENTUM tests cemsidomide in about 100 patients who had prior treatment. On-time enrollment keeps planned 2027 response data in view.
Supportive ifC4T reports that MOMENTUM enrollment is complete by the end of Q1 2027, near its stated target.
Worry ifC4T says enrollment is still open after Q1 2027, or delays initial response data past the second half of 2027.
Why it matters: The 75 µg dose passed its safety review. The next update can show whether the 100 µg dose can also be tested.
Supportive ifThe 2H 2026 update confirms work has started to raise the dose to 100 µg. No new safety issue is reported.
Worry ifC4T reports a safety issue at 100 µg, pauses dose escalation, or delays the planned update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$299 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $723 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,411 loss on $10,000 · 44.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 2 trial tests cemsidomide at its chosen 100 µg dose. Its response rate will test the earlier trial results.
Watch forIn the Phase 2 data, the first response rate assessed by investigators is at least 40%.
Also watch forIn the Phase 2 data, the first response rate assessed by investigators is below 40%.